Viking Therapeutics
VKTX
410 hedge funds and large institutions have $2.43B invested in Viking Therapeutics in 2026 Q1 according to their latest regulatory filings, with 66 funds opening new positions, 156 increasing their positions, 117 reducing their positions, and 69 closing their positions.
239% more call options, than puts
Call options by funds: $241M | Put options by funds: $71M
33% more repeat investments, than reductions
Existing positions increased: 156 | Existing positions reduced: 117
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0.3% less ownership
Funds ownership: 63.64% → 63.34% (-0.3%)
4% less capital invested
Capital invested by funds: $2.53B → $2.43B (-$108M)
4% less first-time investments, than exits
New positions opened: 66 | Existing positions closed: 69
3% less funds holding
Funds holding: 424 → 410 (-14)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$64.2M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
+$57M |
| 3 |
Raymond James Financial
St Petersburg,
Florida
|
+$37.1M |
| 4 |
VPC
Vestal Point Capital
New York
|
+$29.4M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$13.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$24.2M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$23.1M |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
-$21M |
| 4 |
AGP
Artia Global Partners
Miami,
Florida
|
-$17.3M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$17.1M |
VKTX Hedge Fund Activity: Q1 2026 in Review
410 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q1 2026, worth a combined $2.43B — down 4.3% from $2.53B a quarter earlier.
Sellers outnumbered buyers: 69 funds closed out of VKTX and 66 opened new positions — a net loss of 3 holders — while 117 trimmed existing stakes and 156 added.
The largest buyer was Two Sigma Investments, adding an estimated $64.2M. The largest seller was Jane Street, cutting an estimated $24.2M.
- 410 institutional investors held Viking Therapeutics (VKTX) as of Q1 2026, down from 424 in Q4 2025.
- Funds reported $2.43B of Viking Therapeutics stock for Q1 2026, down 4.3% quarter-over-quarter.
- 66 funds opened new Viking Therapeutics positions in Q1 2026 and 69 closed out, a net change of -3 holders.
- The largest Viking Therapeutics buyer in Q1 2026 was Two Sigma Investments, an estimated $64.2M added.
- The largest Viking Therapeutics seller in Q1 2026 was Jane Street, an estimated $24.2M sold.
Based on aggregated 13F filings for Q1 2026.